Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial.
about
Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.Psoriasis pathogenesis and the development of novel targeted immune therapies.A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.Shifting the Focus: The Primary Role of IL-23 in Psoriasis and other Inflammatory Disorders.Guselkumab for psoriasis: a critical appraisal of Phase III studies.Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.Antibodies to watch in 2018.Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Targeting IL-23 in psoriasis: current perspectives.Guselkumab: First Global Approval.Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment.Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
P2860
Q38632657-A829BC5E-6F68-4589-946C-8F5AE60E6523Q46247849-D2F17FE9-CB4D-43EF-848E-74F72EE7A748Q47602117-E62D4280-8A2D-4F7C-98E2-B0F47F2EF387Q47644680-BB3EE34C-53E2-4D3B-BF12-365CD3D46419Q47657450-53662784-103A-4308-8604-D33C04E05993Q47830025-C91BD293-ECAE-4171-BC0C-601DD7855CECQ48104953-7E5E6C93-AC01-40AF-A770-FAC9699C2A63Q48326905-ECC013F5-F1BA-4738-9391-7301011E22D7Q50041283-AD15D502-9B75-4BEE-A543-73F57726BC73Q50086883-01236F81-A7CC-482F-A82A-95922F7B5085Q50099588-118603F5-7AE6-419B-BCF7-1EB3D345C475Q50120289-39D8FF1B-941A-4A17-AB25-D18194DA0294Q52670394-E19EA14B-CB3F-434E-86F8-872384560730Q52689973-60880AFC-9D9C-4C40-BAD7-F5C6BFD080D1Q52695350-E02FFAA0-0432-49C5-A02C-3921CE112A8BQ55060237-A5774D32-1A7A-4861-B5AE-E25C02D49E2BQ55115632-3205367E-C213-4162-8021-659C6B11F33BQ58720009-5B780017-1FD4-498F-9595-5B7002DCC7A6
P2860
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Efficacy and safety of guselku ...... blind, Phase 3 NAVIGATE trial.
@en
type
label
Efficacy and safety of guselku ...... blind, Phase 3 NAVIGATE trial.
@en
prefLabel
Efficacy and safety of guselku ...... blind, Phase 3 NAVIGATE trial.
@en
P2093
P2860
P356
P1476
Efficacy and safety of guselku ...... blind, Phase 3 NAVIGATE trial.
@en
P2093
B Randazzo
R G Langley
P2860
P356
10.1111/BJD.15750
P407
P50
P577
2017-06-21T00:00:00Z